Inari Medical, now part of Stryker, launches Artix™ Thrombectomy System, designed to address a broad spectrum of arterial thrombus cases

Rhea-AI Summary

Inari Medical, now part of Stryker (NYSE: SYK), has launched the Artix™ Thrombectomy System, a new medical device designed for peripheral arterial thrombectomy. The system combines aspiration and mechanical thrombectomy capabilities to address arterial blood clots in the legs, which are life- and limb-threatening emergencies.

The Artix system features a dual mechanical thrombectomy and aspiration toolkit, capable of removing acute to chronic clots in a single session. It includes an 8 Fr. low-profile sheath available in 65cm and 90cm lengths, and an innovative over-the-wire mechanical element. The system also incorporates a covered nitinol mesh funnel to minimize clot migration risk.

The first commercial case using Artix was performed by Dr. Jonathan Bowman at Norwalk Hospital on October 19, 2024. The device aims to overcome limitations of existing therapies, which can lead to ineffective clot retrieval, significant blood loss, vessel trauma, and high rates of lytic use.

Positive

• First-of-its-kind dual mechanical and aspiration thrombectomy system for arterial use
• Potential to replace open surgical repairs in many arterial cases
• Addresses limitations of existing therapies
• Expands treatment options for complex and distal interventions

Negative

• None.

News Market Reaction – SYK

-3.38%

1 alert

-3.38% News Effect

On the day this news was published, SYK declined 3.38%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

PORTAGE, Mich., March 6, 2025 /PRNewswire/ -- Inari Medical, now part of Stryker (NYSE: SYK), a global leader in medical technologies, announced the launch of its Artix Thrombectomy System. Purpose-built for the distinct needs of the peripheral arterial system, Artix is a combined aspiration plus mechanical thrombectomy solution that delivers procedural control and versatility, and is designed to set a new standard for arterial thrombectomy.

An arterial blood clot in the leg is a life- and limb-threatening emergency requiring immediate treatment. However, existing therapies for arterial thromboembolism can lead to:

• Ineffective clot retrieval leading to additional procedures (open surgery or amputation^1,2)
• Significant blood loss¹
• Adverse events such as arterial embolization and vessel trauma^2,3
• High rates of lytic use, which may result in complications^1,2

The Artix System builds on the success of Inari's venous thrombectomy devices and is its inaugural entry into the arterial space. Inari offers a comprehensive toolkit approach to arterial thrombectomy with an innovative, over-the-wire system that provides physicians with the flexibility to aspirate and/or mechanically extract a clot.

Jonathan Bowman, MD FACS, Chief of Vascular at Norwalk Hospital in Norwalk, CT, performed the first commercial case with Artix on October 19, 2024. "The Artix Thrombectomy System marks a significant advancement in peripheral arterial thromboembolism treatment," said Dr. Bowman. "With Artix, I finally have a solution that effectively addresses a wide range of clots while enabling me to maintain vessel access and retain control throughout the entire case. I expect Artix will take the place of open surgical repair in many of my arterial cases."

Key distinctive features of the Artix system include:

• Dual mechanical thrombectomy and aspiration toolkit designed to remove acute to chronic clots in a single session via a streamlined procedure⁴
• Aspiration-capable, 8 Fr. low profile, trackable, kink-resistant sheath in both 65cm and 90cm lengths expands treatment options by enabling more complex and distal interventions
• Innovative over-the-wire mechanical element designed to effectively collect and retrieve acute-to-chronic clot⁴
• Covered nitinol mesh funnel provides temporary flow restriction during the procedure to minimize the risk of arterial clot migration⁵

"There is a real clinical need to address chronic thrombi and decrease the risk of clot migration. Artix will raise the bar of effective arterial thrombectomy," said Tom Tu, MD, Chief Medical Officer of Inari Medical. "We are excited to bring Inari's core competency in thrombectomy to the arterial space with the goal of improving outcomes."

For more information, visit https://www.inarimedical.com/artix-system

About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

On February 19, 2025, Stryker acquired Inari Medical, a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases.

Media contact:
Sherri Oakson
Senior Director, Communications 
MedSurg and Neurotechnology
sherri.oakson@stryker.com 

1. De Donato et al. The INDIAN Trial. Eur J Vasc Endovasc Surg. 2021; 61: 820-828.
2. Heller et al. Percutaneous Mechanical Thrombectomy Using Rotarex Device in Acute Limb Ischemia in Infrainguinal Occlusions. BioMed Research International. 2017.
3. Olinic et al. Acute Limb Ischemia: An Update on Diagnosis and Management. J Clin Med. 2019.
4. Designed to remove acute to chronic arterial clots. According to benchtop testing compared to control. Internal data on file. Narula et al. JACC 2018;72:2153-63
5. According to benchtop testing compared to control. Internal data on file. NOTE: To attempt to minimize risk of arterial embolization of blood clots, use of a device that entraps clots may potentially be helpful, but this has not yet been demonstrated to be effective in the arterial system.

Dr. Jonathan Bowman is a paid consultant of Inari Medical. All views and opinions expressed here by Dr. Jonathan Bowman are his own and do not represent those of Inari Medical.

Indications for Use: The Artix thin-walled sheath is indicated for: (1) The non-surgical removal of emboli and thrombi from blood vessels. (2) Injection, infusion and/or aspiration of contrast media and other fluids into or from a blood vessel. (3) Use as a conduit for endovascular devices. (4) Use in facilitating the insertion and guidance of an intravascular catheter into a selected blood vessel. The funnel provides temporary vascular occlusion during these and other angiographic procedures. The Artix thin-walled sheath is intended for use in the peripheral vasculature. The Artix MT thrombectomy device is indicated for (1) the non-surgical removal of emboli and thrombi from a blood vessel; and (2) injection, infusion, and/or aspiration of contrast media and other fluids into or from a blood vessel. The Artix MT thrombectomy device is intended for use in the peripheral vasculature. The Artix AX aspiration catheter is indicated for (1) the non-surgical removal of emboli and thrombi from blood vessels; and (2) injection, infusion, and/or aspiration of contrast media and other fluids into or from a blood vessel. The Artix AX aspiration catheter is intended for use in the peripheral vasculature. The FlowSaver blood return system is used with Inari Medical catheters and sheaths for autologous blood transfusion.

Review complete Instructions for Use, Indications for Use, Warnings, Precautions, Possible Adverse Effects and Contraindications prior to use of these products.

View original content to download multimedia:https://www.prnewswire.com/news-releases/inari-medical-now-part-of-stryker-launches-artix-thrombectomy-system-designed-to-address-a-broad-spectrum-of-arterial-thrombus-cases-302394987.html

SOURCE Stryker

FAQ

What is the Artix Thrombectomy System launched by Stryker (SYK)?

Artix is a combined aspiration and mechanical thrombectomy system designed for peripheral arterial blood clots, featuring dual thrombectomy capabilities and an 8 Fr. low-profile sheath in 65cm and 90cm lengths.

When was the first commercial case of Stryker's (SYK) Artix system performed?

The first commercial case using the Artix Thrombectomy System was performed on October 19, 2024, by Dr. Jonathan Bowman at Norwalk Hospital.

What are the key features of Stryker's (SYK) new Artix Thrombectomy System?

Key features include dual mechanical thrombectomy and aspiration capabilities, an 8 Fr. low-profile sheath, an over-the-wire mechanical element, and a covered nitinol mesh funnel to prevent clot migration.

How does the Artix system improve upon existing arterial thrombectomy treatments for SYK?

Artix addresses limitations of existing treatments by reducing the risk of ineffective clot retrieval, minimizing blood loss, decreasing vessel trauma, and potentially lowering the need for lytic use.

What clinical advantages does Stryker's (SYK) Artix system offer for arterial procedures?

Artix offers the ability to remove both acute and chronic clots in a single session, maintains vessel access throughout procedures, and may replace open surgical repair in many arterial cases.